The rise of Sildenafil initially fueled a surge for the drug industry, however recent changes present a uncertain scenario for shareholders. Off-patent alternatives are eating into revenue, and ongoing litigation add https://jimisef454638.idblogmaker.com/39942615/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-play